{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:51:20Z","timestamp":1793364680349,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T00:00:00Z","timestamp":1497830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venlafaxine is a commonly used antidepressant agent. We aimed to provide detailed information on the associations between venlafaxine dose and concentrations of venlafaxine, by patient age and sex. From a therapeutic drug monitoring (<jats:styled-content style=\"fixed-case\">TDM<\/jats:styled-content>) database located at Odense University Hospital, Denmark, we identified all adults for whom the treating physician had requested clinical advice on the <jats:styled-content style=\"fixed-case\">TDM<\/jats:styled-content> result for venlafaxine between 2002 and 2012. We identified 1077 <jats:styled-content style=\"fixed-case\">TDM<\/jats:styled-content> samples of venlafaxine from 334 males and 743 females (median age 45\u00a0years), and the median daily dose was 225\u00a0mg. Median plasma concentration of venlafaxine and o\u2010desmethylvenlafaxine (<jats:styled-content style=\"fixed-case\">ODV<\/jats:styled-content>) was 306\u00a0nmol\/L and 861\u00a0nmol\/L, respectively. The median dose\u2010corrected serum level for venlafaxine was 1.49\u00a0nmol\/L\/mg., while the dose\u2010corrected serum level of men and women were 1.21\u00a0nmol\/L\/mg and 1.60\u00a0nmol\/L\/mg, respectively. The dose\u2010corrected sum of venlafaxine and <jats:styled-content style=\"fixed-case\">ODV<\/jats:styled-content> was 8.91\u00a0nmol\/L\/mg (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 6.56\u201312.26) <jats:italic>versus<\/jats:italic> 5.52\u00a0nmol\/L\/mg (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 4.16\u20137.52) for patients above 64\u00a0years and below the age of 65\u00a0years, respectively. Dose\u2010corrected plasma concentrations of venlafaxine and <jats:styled-content style=\"fixed-case\">ODV<\/jats:styled-content> are increased to a clinically significant degree in patients above the age of 64, and initiation of venlafaxine therapy in the elderly should be made cautiously and supported by drug measurements.<\/jats:p>","DOI":"10.1111\/bcpt.12796","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T07:26:48Z","timestamp":1491895608000},"page":"298-302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships"],"prefix":"10.1111","volume":"121","author":[{"given":"Morten Rix","family":"Hansen","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacy University of Southern Denmark Odense Denmark"},{"name":"Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida Berglund","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Damkier","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark"},{"name":"Department of Clinical Research University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,19]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.174.4.307"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.11.033"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.5.503"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00113-4"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00173.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.02.007"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937020-00004"},{"key":"e_1_2_5_11_1","unstructured":"D.SP.NR 23315. PRODUKTRESUM\u00c9 for Venlafaxin \u201cOrifarm\u201d h\u00e5rde depotkapsler (Orifarm Generics). Sundhedsstyrelsen (Danish Health and Medicines Authority); 2016"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200208000-00014"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31819114ea"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1317-9"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1301366"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0829-y"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140197"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000022097"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2012.01.001"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852912001010"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:15:15Z","timestamp":1695546915000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,19]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/bcpt.12796"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12796","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,19]]},"assertion":[{"value":"2017-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}